Published in Clin J Pain on September 01, 2001
Expecting a good quality of life in health: assessing people with diverse diseases and conditions using the WHOQOL-BREF. Health Expect (2011) 1.09
Exploring the relationship between spirituality, coping, and pain. J Behav Med (2007) 1.06
Comparative effectiveness of CBT interventions for co-morbid chronic pain & insomnia: a pilot study. Behav Res Ther (2012) 0.91
An examination of the synergy of pain and PTSD on quality of life: additive or multiplicative effects? Pain (2008) 0.88
Quality of life in mentally ill, physically ill and healthy individuals: the validation of the Greek version of the World Health Organization Quality of Life (WHOQOL-100) questionnaire. Ann Gen Psychiatry (2009) 0.80
The minimal clinical important difference in the World Health Organization Quality of Life instrument--100. Support Care Cancer (2012) 0.78
A measure for quality of life assessment in chronic pain: preliminary properties of the WHOQOL-pain. J Behav Med (2008) 0.77
Predicting the Trajectories of Perceived Pain Intensity in Southern Community-Dwelling Older Adults: The Role of Religiousness. Res Aging (2013) 0.75
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet (1992) 3.30
Problems in assessing contents of metered dose inhalers. BMJ (1993) 3.07
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res (1979) 2.61
Starch-Ampicillin Agar for the Quantitative Detection of Aeromonas hydrophila. Appl Environ Microbiol (1985) 1.72
Minimum standards for the management of cleft lip and palate: efforts to close the audit loop. Royal College of Surgeons of England. Ann R Coll Surg Engl (1996) 1.72
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet (1987) 1.48
Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease. Neurosci Lett (1990) 1.47
Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci (1999) 1.45
Influence of surgeon's experience on speech outcome in cleft lip and palate. Lancet (1999) 1.44
Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci (2008) 1.43
Migraine after bone-marrow transplantation. Lancet (1989) 1.43
Updated guidelines for the management of Parkinson's disease. Hosp Med (2001) 1.41
The incidence of impacted teeth. A survey at Harlem hospital. Oral Surg Oral Med Oral Pathol (1970) 1.35
Submandibular duct sialolith of unusual size and shape. J Oral Surg (1975) 1.31
Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev (2003) 1.30
A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology (1999) 1.25
Sexual difficulties of chronic pain patients. Clin J Pain (2001) 1.25
Long-term treatment of parkinsonism with bromocriptine. Lancet (1978) 1.24
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 3: speech outcomes. Cleft Palate Craniofac J (2001) 1.21
Systematic review of outpatient services for chronic pain control. Health Technol Assess (1997) 1.19
Encephalopathy associated with ifosphamide/mesna therapy. Lancet (1985) 1.17
Xenobiotic metabolism in motor neuron disease. Lancet (1988) 1.16
Xenobiotic metabolism in Parkinson's disease. Neurology (1989) 1.16
Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm (2000) 1.15
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 4: outcome comparisons, training, and conclusions. Cleft Palate Craniofac J (2001) 1.12
Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm. Br J Ophthalmol (1990) 1.10
The development of a battery of measures for assessing physical functioning of chronic pain patients. Pain (1994) 1.08
Spinal cord stimulation and the relief of chronic pain. J Neurol Neurosurg Psychiatry (1987) 1.06
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 1: background and methodology. Cleft Palate Craniofac J (2001) 1.03
Extrapyramidal reactions to anti-inflammatory drugs. J Neurol Neurosurg Psychiatry (1988) 1.02
Smoking habits of Florida physicians revisited. JFMA (1972) 1.01
Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. Science (1979) 1.01
Skin delivery of oestradiol from deformable and traditional liposomes: mechanistic studies. J Pharm Pharmacol (1999) 1.01
Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions. Cancer (1970) 1.01
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut (2005) 1.00
Stridor during dystonic phases of Parkinson's disease. J Neurol Neurosurg Psychiatry (1987) 1.00
Patients' and professionals' understandings of the causes of chronic pain: blame, responsibility and identity protection. Soc Sci Med (1997) 0.99
Motoneurone disease as manifestation of pesticide toxicity. Lancet (1987) 0.99
Idiopathic dysautonomia treated with intravenous gammaglobulin. Lancet (1996) 0.98
Derepression of synthesis of the aminoacyl-transfer ribonucleic acid synthetases for the branched-chain amino acids of Escherichia coli. J Bacteriol (1974) 0.98
Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology (1990) 0.98
Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro. J Pharm Pharmacol (2001) 0.98
Bax inhibitor 1 in apoptosis and disease. Oncogene (2011) 0.97
Loss of APC protein expressed by human colonic epithelial cells and the appearance of a specific low-molecular-weight form is associated with apoptosis in vitro. Int J Cancer (1994) 0.97
Are the Peer Assessment Rating Index and the Index of Treatment Complexity, Outcome, and Need suitable measures for orthognathic outcomes? Eur J Orthod (2006) 0.96
Colorectal carcinogenesis: sequential steps in the in vitro immortalization and transformation of human colonic epithelial cells (review). Anticancer Res (1990) 0.95
Characterization of the Aeromonas hydrophila group isolated from retail foods of animal origin. J Clin Microbiol (1989) 0.95
The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. Oncogene (2010) 0.95
Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis (2003) 0.94
S-methylation in motorneuron disease and Parkinson's disease. Lancet (1989) 0.94
Plagiarism, retraction and the future. Hum Reprod (2011) 0.94
Nuclear BAG-1 expression inhibits apoptosis in colorectal adenoma-derived epithelial cells. Apoptosis (2005) 0.94
Terpene penetration enhancers in propylene glycol/water co-solvent systems: effectiveness and mechanism of action. J Pharm Pharmacol (1995) 0.93
Characterization of dihydrates prepared from carbamazepine polymorphs. J Pharm Sci (1996) 0.92
Opiate reduction in chronic pain patients: a comparison of patient-controlled reduction and staff controlled cocktail methods. Pain (1994) 0.92
Hyponatraemia as a cause of reversible ataxia. Br Med J (Clin Res Ed) (1986) 0.92
Deterioration of Wilson's disease following the start of penicillamine therapy. Arch Neurol (1989) 0.92
Toxicity of sulphur-containing compounds to neuronal cell lines. J Neurol Sci (1995) 0.91
Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer (1996) 0.91
Surgery for Parkinson's disease: lack of reliable clinical trial evidence. J Neurol Neurosurg Psychiatry (2003) 0.91
Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet (1987) 0.90
Prospects in NSAID-derived chemoprevention of colorectal cancer. Biochem Soc Trans (2005) 0.90
Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. Hosp Med (1998) 0.90
Skin hydration and possible shunt route penetration in controlled estradiol delivery from ultradeformable and standard liposomes. J Pharm Pharmacol (2001) 0.90
Bonding of metal attachments to teeth for treatment of mandibular fractures. J Oral Surg (1974) 0.89
Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans (2005) 0.89
An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol (1995) 0.88
Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm (2004) 0.88
IGFBP-3 and apoptosis--a license to kill? Apoptosis (2001) 0.88
The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells. Cell Death Dis (2012) 0.87
Skin delivery of oestradiol from lipid vesicles: importance of liposome structure. Int J Pharm (2000) 0.87
The neuropathy of the critically ill. Br Med J (Clin Res Ed) (1986) 0.87
In vitro effect of the cysteine metabolites homocysteic acid, homocysteine and cysteic acid upon human neuronal cell lines. Neurotoxicology (1998) 0.87
The chewing stick: its uses and relationship to oral health. J Prev Dent (1978) 0.86
Acute epidural abscess. Am J Emerg Med (1987) 0.86
Panfacial cellulitis with contralateral orbital cellulitis and blindness after tooth extraction. J Oral Surg (1977) 0.86
Stochiometrically governed molecular interactions in drug: poloxamer solid dispersions. Int J Pharm (2010) 0.86
Self-attempted endodontics--a case report. ASDC J Dent Child (1969) 0.86
Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther (1979) 0.86
Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen. J Control Release (1998) 0.85
Lipid peroxidation and Parkinson's disease. Lancet (1986) 0.85
The process of orthognathic care in an NHS region. Ann R Coll Surg Engl (2009) 0.85
Transcriptional down-regulation of the retinoblastoma protein is associated with differentiation and apoptosis in human colorectal epithelial cells. Br J Cancer (2001) 0.85
Mammographic examinations (4030): ten-year clinical experience in a community medical center. Ann Surg (1973) 0.85
Enhancement by terpenes of 5-fluorouracil permeation through the stratum corneum: model solvent approach. J Pharm Pharmacol (1998) 0.85
Cytochrome P450 1B1 mRNA in the human central nervous system. Mol Pathol (1998) 0.84
Mechanistic study into the enhanced transdermal permeation of a model beta-blocker, propranolol, by fatty acids: a melting point depression effect. Int J Pharm (2001) 0.84
BAG-1 interacts with the p50-p50 homodimeric NF-κB complex: implications for colorectal carcinogenesis. Oncogene (2011) 0.84
Nomalike lesion in a patient with chronic lymphocytic leukemia. Review of the literature and report of a case. Oral Surg Oral Med Oral Pathol (1976) 0.84
Chromosomal localisation of genes coding for human and mouse liver cytosolic cysteine dioxygenase. Ann Hum Genet (1996) 0.84
Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin Cancer Res (1997) 0.84
Combined phenyl silane and immunoaffinity column cleanup with liquid chromatography for determination of ochratoxin A in roasted coffee: collaborative study. J AOAC Int (2001) 0.84
Intracellular or intercellular localization of the polar pathway of penetration across stratum corneum. J Pharm Sci (1998) 0.83
Renal localisation of rat cysteine dioxygenase. Nephron (2001) 0.83
Plasma membrane phospholipid integrity and orientation during hypoxic and toxic proximal tubular attack. Kidney Int (1999) 0.83
Human cysteine dioxygenase type I: primary structure derived from base sequencing of cDNA. Biochim Biophys Acta (1994) 0.83
Parkinson's disease: clinical and therapeutic aspects. Curr Opin Neurol Neurosurg (1992) 0.83
Familial paroxysmal dystonia induced by exercise. J Neurol Neurosurg Psychiatry (1984) 0.83